Harnessing the RNA-Binding Properties of Cas13a for HIV-1 Self-Testing
利用 Cas13a 的 RNA 结合特性进行 HIV-1 自检
基本信息
- 批准号:10456229
- 负责人:
- 金额:$ 88.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAcquired Immunodeficiency SyndromeAcuteAddressBacteriaBindingBiologicalBiological AssayBiologyBloodCRISPR/Cas technologyCar PhoneCellular PhoneChronicClinicalClustered Regularly Interspaced Short Palindromic RepeatsComplexCryopreservationDNADengueDetectionDevelopmentDevicesDiagnosticDiagnostic testsDyesEarly DiagnosisEconomically Deprived PopulationEpidemicEscherichia coliFailureFluorescenceFundingGenomeGoalsGoldGrantGuide RNAHIVHIV GenomeHIV-1HomeHomologous GeneHumanHuman immunodeficiency virus testIncidenceIndividualInfectionInterruptionKnowledgeLaboratoriesLifeLiquid substanceMeasurementMeasuresMethodsMicroscopyMissionMonitorOligonucleotidesPatientsPhasePlasmaProceduresPropertyProteinsPublic HealthRNARNA BindingRNA purificationRecombinantsReporterReproducibilityResearchResearch SupportResource-limited settingReverse TranscriptionRibonucleasesSamplingScientistSerumSiteStructureSystemTechnologyTemperatureTestingUnited States National Institutes of HealthViral Load resultWhole BloodWorkZIKAacute infectionassay developmentbasechronic infectioncohortdesigndetection methoddetection platformfluorophorehealthspanhome testinnovationisothermal amplificationlensmicrobialmultidisciplinarynew technologynovelpreferencereagent testingself testingstability testingviral RNAviral detection
项目摘要
PROJECT ABSTRACT
Current HIV-1 RNA detection relies on reverse transcription before PCR-based amplification, which introduces
unwanted variables and cannot be easily performed outside a laboratory. The central hypothesis of this
application is that the RNA-binding properties of newly discovered CRISPR/Cas13a proteins are suitable for
sensitive at-home detection of HIV-1 RNAs without employing RT or amplification steps. This hypothesis was
formulated on the basis of the recent discovery by the Doudna Lab that Cas13a binds and cleaves target
single-stranded RNAs in a sequence-specific manner (cis cleavage) and subsequently exerts general RNase
activity (trans cleavage) that can be exploited for fluorescence-based measurement of the target RNA. In
unpublished preliminary results, the Ott/Doudna Labs also show that recombinant Cas13a in combination with
HIV-1-specific guide RNAs (crRNAs) enables sensitive detection of HIV-1 RNAs. The central hypothesis will be
tested in a two-pronged, highly milestone-driven approach: in the innovation phase (R61), two aims will define
the optimal Cas13a homologue/crRNA combination for reliable HIV-1 detection and optimize the read-out
technology for home use. Aim 1: To optimize guide RNA (crRNA) and Cas13a protein selection. The applicants
will design HIV-specific crRNAs recognizing conserved accessible regions of the target HIV-1 genome and
systematically test Cas13a homologs from different bacteria for HIV-specific cis and trans cleavage. At the end
of the R61 period in order to progress to the R33 phase, the team will have identified ≥3 optimized crRNA
spacer sequences in the HIV-1 genome, selected ≥1 Cas13a homologs with high HIV-specific cis- and trans-
ssRNA cleavage rates with low background. Aim 2: To enhance read-out technology and optimize for self-
testing. In preliminary results, the Fletcher Lab measured E. coli DNA after PCR amplification detecting
fluorescence from an intercalating dye with iPhone-based technology. The applicants will define the optimal
sequence for trans-cleavage by Cas13a versus human RNase proteins as well as optimize fluorophore and
quencher moieties on the detection oligonucleotide for measurements with mobile phone-based reverse lens
microscopy (CellScope). At the end of the R61 period in order to progress to the R33 phase, ≥1 detection
sequence will have been identified and ≥1 fluorescence/quencher combination will have been optimized for
CellScope detection. The R33 phase consists of one aim, rigorously comparing Cas13a-CellScope results with
conventional viral load assays in acutely and chronically infected individuals and adapting the method to home
use. Aim 3: To apply optimized Cas13a assay parameters towards building a self-testing device using clinical
samples. The team will optimize HIV-1 RNA detection in the context of plasma, serum and whole blood,
enhance stability of the test system at room temperature and analyze cryopreserved and fresh patient samples
provided by Dr. Deeks from the SCOPE cohort. It is anticipated that the work completed during this grant will
develop fundamentally new technology to enable early and frequent monitoring of HIV-1 infection at home.
项目摘要
当前的 HIV-1 RNA 检测依赖于基于 PCR 的扩增之前的逆转录,这引入了
不需要的变量,并且不能在实验室外轻易地进行该中心假设。
应用是新发现的 CRISPR/Cas13a 蛋白的 RNA 结合特性适用于
无需使用 RT 或扩增步骤即可在家中灵敏地检测 HIV-1 RNA。
根据 Doudna 实验室最近发现的 Cas13a 结合和切割靶标制定的
以序列特异性方式(顺式切割)形成单链 RNA,随后发挥通用 RNase 作用
活性(反式切割),可用于基于荧光的目标 RNA 测量。
Ott/Doudna 实验室未发表的初步结果还表明,重组 Cas13a 与
HIV-1 特异性指导 RNA (crRNA) 能够灵敏地检测 HIV-1 RNA 的中心假设是。
以双管齐下、高度里程碑驱动的方法进行测试:在创新阶段(R61),将定义两个目标
用于可靠 HIV-1 检测并优化读数的最佳 Cas13a 同源物/crRNA 组合
目标 1:优化引导 RNA (crRNA) 和 Cas13a 蛋白选择。
将设计 HIV 特异性 crRNA,识别目标 HIV-1 基因组的保守可及区域,并且
最后稳定地测试来自不同细菌的 Cas13a 同源物的 HIV 特异性顺式和反式切割。
为了进入 R33 阶段,团队将鉴定出 ≥3 个优化的 crRNA
HIV-1基因组中的间隔序列,选择≥1个具有高HIV特异性顺式和反式的Cas13a同源物
目标 2:增强读出技术并优化自我检测。
初步结果是,弗莱彻实验室在PCR扩增检测后测量了大肠杆菌DNA。
申请人将使用基于 iPhone 的技术来确定嵌入染料的荧光。
Cas13a 与人 RNase 蛋白的反式切割序列以及优化荧光团和
检测寡核苷酸上的猝灭剂部分,用于使用基于手机的反向镜头进行测量
在 R61 期结束时进行显微镜检查 (CellScope),以便进入 R33 期,≥1 次检测。
序列将被识别,并且 ≥1 荧光/猝灭剂组合将被优化
CellScope 检测包含一个目标,将 Cas13a-CellScope 结果与
对急性和慢性感染个体进行常规病毒载量测定并使该方法适应家庭
目标 3:应用优化的 Cas13a 测定参数来构建临床自检设备。
该团队将优化血浆、血清和全血中的 HIV-1 RNA 检测,
增强测试系统在室温下的稳定性并分析冷冻保存的新鲜患者样本
由 SCOPE 团队的 Deeks 博士提供,预计在这笔资助期间完成的工作将
从根本上开发新技术,以便能够对家庭中的 HIV-1 感染进行早期和频繁的监测。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Melanie Maria Ott其他文献
Melanie Maria Ott的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Melanie Maria Ott', 18)}}的其他基金
Modeling intestinal dysfunction in HIV infection with organoid technology
利用类器官技术模拟 HIV 感染的肠道功能障碍
- 批准号:
10542390 - 财政年份:2020
- 资助金额:
$ 88.94万 - 项目类别:
Modeling intestinal dysfunction in HIV infection with organoid technology
利用类器官技术模拟 HIV 感染的肠道功能障碍
- 批准号:
10322720 - 财政年份:2020
- 资助金额:
$ 88.94万 - 项目类别:
Modeling intestinal dysfunction in HIV infection with organoid technology
利用类器官技术模拟 HIV 感染的肠道功能障碍
- 批准号:
9894660 - 财政年份:2020
- 资助金额:
$ 88.94万 - 项目类别:
Modeling intestinal dysfunction in HIV infection with organoid technology
利用类器官技术模拟 HIV 感染的肠道功能障碍
- 批准号:
10083740 - 财政年份:2020
- 资助金额:
$ 88.94万 - 项目类别:
Exploring HIV-associated Neurocognitive Disorder (HAND) and HIV Latency at the Single Cell Level in Cerebral Organoids
在脑类器官的单细胞水平上探索 HIV 相关神经认知障碍 (HAND) 和 HIV 潜伏期
- 批准号:
10466829 - 财政年份:2019
- 资助金额:
$ 88.94万 - 项目类别:
Harnessing the RNA-Binding Properties of Cas13a for HIV-1 Self-Testing
利用 Cas13a 的 RNA 结合特性进行 HIV-1 自检
- 批准号:
10423661 - 财政年份:2019
- 资助金额:
$ 88.94万 - 项目类别:
Exploring HIV-associated Neurocognitive Disorder (HAND) and HIV Latency at the Single Cell Level in Cerebral Organoids
在脑类器官的单细胞水平上探索 HIV 相关神经认知障碍 (HAND) 和 HIV 潜伏期
- 批准号:
10678898 - 财政年份:2019
- 资助金额:
$ 88.94万 - 项目类别:
Single-Cell Transcriptomics of Non-Activated Latently Infected T cells Isolated from HIV+ Drug Users
从 HIV 吸毒者中分离出的非激活潜伏感染 T 细胞的单细胞转录组学
- 批准号:
10548752 - 财政年份:2019
- 资助金额:
$ 88.94万 - 项目类别:
Harnessing the RNA-Binding Properties of Cas13a for HIV-1 Self-Testing
利用 Cas13a 的 RNA 结合特性进行 HIV-1 自检
- 批准号:
9982198 - 财政年份:2018
- 资助金额:
$ 88.94万 - 项目类别:
相似国自然基金
从CD4+、CD8+T细胞免疫活化分子及其上游调控因子表达探究健脾祛湿法治疗艾滋病免疫调节机制
- 批准号:81460716
- 批准年份:2014
- 资助金额:48.0 万元
- 项目类别:地区科学基金项目
HAART过程中HCV复制增强与肝细胞MAVS抗病毒通路的关系研究
- 批准号:81201286
- 批准年份:2012
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Hepatotoxic mechanisms of anti-HIV- and anti-COVID-19 drugs and substance use disorders
抗 HIV 和抗 COVID-19 药物和物质使用障碍的肝毒性机制
- 批准号:
10684434 - 财政年份:2023
- 资助金额:
$ 88.94万 - 项目类别:
At the Intersection of HIV and COVID-19: Medicaid Data as a Complement to Cohort Studies
HIV 和 COVID-19 的交叉点:医疗补助数据作为队列研究的补充
- 批准号:
10548472 - 财政年份:2022
- 资助金额:
$ 88.94万 - 项目类别:
A randomized controlled pilot study to examine the impact of a filmed dramatized story intervention (telenovela/soap opera) for HIV prevention in Latinas
一项随机对照试点研究,旨在检验电影化故事干预(电视剧/肥皂剧)对拉丁裔艾滋病毒预防的影响
- 批准号:
10403030 - 财政年份:2022
- 资助金额:
$ 88.94万 - 项目类别:
A randomized controlled pilot study to examine the impact of a filmed dramatized story intervention (telenovela/soap opera) for HIV prevention in Latinas
一项随机对照试点研究,旨在检验电影化故事干预(电视剧/肥皂剧)对拉丁裔艾滋病毒预防的影响
- 批准号:
10673607 - 财政年份:2022
- 资助金额:
$ 88.94万 - 项目类别:
Adolescent-tailored HIV treatment and prevention strategies in South Africa: projecting clinical benefits and value
南非针对青少年的艾滋病毒治疗和预防策略:预测临床效益和价值
- 批准号:
10619497 - 财政年份:2022
- 资助金额:
$ 88.94万 - 项目类别: